Ligand Pharmaceuticals Incorporated
LGNDV
NASDAQ Global Market50.00
USD
- -
- -
Ligand Pharmaceuticals Incorporated
LGNDV
(NASDAQ Global Market)
Recent
price
50.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) is a biopharmaceutical company that invests in the clinical development and commercialization of high-value medicines; enables scientific advancement through financing, licensing its proprietary technologies, and managing one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, encompassing more than 90 partnered commercial and development-stage programs across disease areas including cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and rare conditions; and licenses Captisol and NITRICIL technology platforms with broad applicability in drug development to a network of biopharmaceutical partners, including Amgen, Merck, Pfizer, Takeda, Gilead Sciences, and Baxter International. Core products and services derive from royalties on over 30 commercial programs marketed in more than 70 countries, such as Kyprolis (Amgen), Veklury (Gilead), Nexterone (Baxter), Evomela (Acrotech Biopharma), Duavee (Pfizer), and QARZIBA (Recordati); Captisol materials sales for drug solubility and stability enhancement in formulations like Noxafil-IV; and milestone payments alongside contract revenue from alliances covering partnered oncology assets including BOT/BAL (Agenus), Ohtuvayre (Verona), and early-stage immuno-oncology programs. Founded in 1987 and headquartered in Jupiter, FL, the company operates globally with a focus on mid- to late-stage assets, generating revenue streams from royalties, Captisol sales, and technology licensing while maintaining an infrastructure-light model. Recent developments include the July 2024 acquisition of APEIRON Biologics AG for $100 million, adding royalty rights to the commercial oncology drug QARZIBA marketed in 35 countries and a $4 million investment in APEIRON spin-off invIOs Holding AG for immuno-oncology assets; a $100 million royalty financing agreement with Agenus in 2024 supporting BOT/BAL clinical development with entitlements to royalties on six partnered oncology programs from Bristol Myers Squibb, Gilead, Incyte, Merck, and UroGen; Pelthos Therapeutics' July 2025 launch of ZELSUVMI following its merger with Channel Therapeutics, where Ligand holds a 56% stake and 13% worldwide royalty; a $75 million financing in Castle Creek Biosciences for D-Fi in dystrophic epidermolysis bullosa; and Orchestra BioMed's $70 million financing from Ligand and Medtronic for cardiology programs AVIM and Virtue SAB, alongside Merck's acquisition of partner Verona Pharma to accelerate Ohtuvayre in COPD. In Q2 2025, royalties rose 57% year-over-year to $36.4 million, prompting raised full-year 2025 revenue guidance to $225-$235 million, underscoring the strength of its diversified royalty aggregation strategy.